Need Assistance?

US & Canada:
+
UK: +

FAQs

Resources

Our Highlights

GMP Grade Efficient workshop for GMP production.
Optimal Prices Buying products on this site guarantees the best price!
Commercial Batches Independent GMP manufacturing suites that handle commercial batches
Prompt Delivery Warehouses in multiple cities to ensure timely delivery
Flexible Quantity Quantities available from milligrams to ton

Application Area

ACTH 1-17

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

ACTH (1-17) is a peptide fragment of ACTH, a tropic hormone produced by the anterior pituitary.

Category

Peptide Inhibitors

Catalog number

BAT-006110

CAS number

7266-47-9

Molecular Formula

C95H145N29O23S

Molecular Weight

2093.41

Size	Price	Stock	Quantity
2.5 mg	$239	In stock
5 mg	$419	In stock

Specification
Reference Reading

IUPAC Name

(4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-[[2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-oxopentanoic acid

Synonyms

Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg; Alpha1-17-ACTH; a1-17-Corticotropin; L-seryl-L-tyrosyl-L-seryl-L-methionyl-L-alpha-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophyl-glycyl-L-lysyl-L-prolyl-L-valyl-glycyl-L-lysyl-L-lysyl-L-arginine; 1-Ala-17-Lys-ACTH 4-amino-n-butylamide; 1-beta-Alanine-17-(L-2,6-diamino-N-(4-aminobutyl)hexanamide)-alpha1-17-corticotrophin; alsactide; Synchrodyn; Adrenocorticotropic Hormone Fragment 1-17 human, rat

Appearance

Lyophilized Powder

Purity

98%

Density

1.5±0.1 g/cm3

Boiling Point

1891.5±75.0°C at 760 mmHg

Sequence

SYSMEHFRWGKPVGKKR

Storage

Store at -20°C

Solubility

Soluble in Water

InChI

InChI=1S/C95H145N29O23S/c1-53(2)78(91(144)109-49-75(128)111-62(22-9-12-35-96)81(134)113-63(23-10-13-36-97)82(135)117-68(93(146)147)26-16-39-106-95(102)103)123-90(143)74-27-17-40-124(74)92(145)67(24-11-14-37-98)112-76(129)48-108-80(133)71(44-56-46-107-61-21-8-7-20-59(56)61)120-83(136)64(25-15-38-105-94(100)101)114-86(139)70(42-54-18-5-4-6-19-54)119-88(141)72(45-57-47-104-52-110-57)121-84(137)65(32-33-77(130)131)115-85(138)66(34-41-148-3)116-89(142)73(51-126)122-87(140)69(118-79(132)60(99)50-125)43-55-28-30-58(127)31-29-55/h4-8,18-21,28-31,46-47,52-53,60,62-74,78,107,125-127H,9-17,22-27,32-45,48-51,96-99H2,1-3H3,(H,104,110)(H,108,133)(H,109,144)(H,111,128)(H,112,129)(H,113,134)(H,114,139)(H,115,138)(H,116,142)(H,117,135)(H,118,132)(H,119,141)(H,120,136)(H,121,137)(H,122,140)(H,123,143)(H,130,131)(H,146,147)(H4,100,101,105)(H4,102,103,106)/t60-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,78-/m0/s1

InChI Key

MXNMAFWEFLFAJN-QBQLSIIBSA-N

Canonical SMILES

CC(C)C(C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCNC(=N)N)C(=O)O)NC(=O)C1CCCN1C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CC5=CNC=N5)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CO)N

1. ACTH 1-17 effects in psychogenic impotence

V Montanini, C Carani, M F Celani, P Marrama, G F Baraghini, D Cavani Ric Clin Lab . 1984 Apr-Jun;14(2):233-8.

The purpose of this study was to investigate the effects of repeated administrations of ACTH 1-17 (Syncrodyn 1-17) on sexual and endocrine function in men with psychogenic impotence. Twenty adult impotent men from 21 to 48 years volunteered for this study; organic causes of erectile impotence were excluded in each subject. Ten subjects were treated with ACTH 1-17 (100 micrograms i.m. daily for 15 days during 6 consecutive months), whereas saline was injected in the control group (10 subjects) following the same protocol. Clinical and endocrine evaluation were performed before and at the end of treatment. Serum levels of LH, FSH, PRL, testosterone (T) and cortisol were measured by RIA methods. To investigate diurnal rhythms of T and cortisol, blood samples were taken at 0800 and at 1800. In ACTH 1-17-treated men a significant improvement in sexual function was shown when compared with the control group (p less than 0.05); moreover, both anxiety and fatigability were lowered by ACTH 1-17 administration. ACTH 1-17 did not affect basal levels of LH, FSH, PRL, T and cortisol, whereas the diurnal variation of T, which was absent before treatment in both treated and control group, was restored. No changes in clinical and endocrine parameters were shown after placebo injections. Our data emphasize that the chronopharmacological action of ACTH 1-17 may positively affect sexual function and circadian T rhythmicity in men with psychogenic impotence.

2. ACTH 1-17 effects on intermediary metabolites in healthy subjects

P Melga, R Prando, P Buzzo, V Cheli Ric Clin Lab . 1984 Apr-Jun;14(2):175-80. doi: 10.1007/BF02904970.

Some acute and chronic metabolic effects of a new ACTH analogue (ACTH 1-17, Synchrodyn) were evaluated in healthy subjects and compared to those of the synthetic fragment ACTH 1-24. The peptides were injected at doses reportedly comparable with regard to their corticotropic effect, i.e. 100 micrograms ACTH 1-17 and 250 micrograms ACTH 1-24. A similar increase in blood glucose, NEFA and ketone bodies concentrations, without any significant modification of insulin, C-peptide and glucagon levels, was observed after injecting both peptides. The chronic treatment with ACTH 1-24 induced a significant increase in basal lactate, pyruvate and alanine blood concentrations. The levels of these metabolites resulted unaffected or slightly reduced after the corresponding treatment with ACTH 1-17. Our data are compatible with a certain degree of exhaustion of the adrenocortical reserve or, alternatively, a resetting of the circadian cortisol rhythm after prolonged treatment with the ACTH 1-17 analogue.

3. Positive inotropic effects of an ACTH analogue (ACTH 1-17) on myocardial performance

O Di Stefano, C Signorini, G Levi, S Tosoni, G Cardone Ric Clin Lab . 1985 Oct-Dec;15(4):349-56. doi: 10.1007/BF03029150.

The aim of the present investigation was to study the effects of a single 100-micrograms i.v. administration of the synthetic heptadecapeptide [beta-Ala1-Lys17]ACTH1-17-4-amino-N-butylamide (ACTH 1-17) on the left ventricular performance. The systolic time intervals (STI) were recorded in 20 healthy adult young subjects (10 treated with ACTH 1-17 and 10 receiving placebo) before as well as 20, 40, 60 and 80 min after the i.v. ACTH 1-17 or placebo infusion. The STI were recorded immediately after blood withdrawal for measuring cortisol, aldosterone, adrenaline and noradrenaline plasma levels. A highly significant statistical difference was demonstrated for preejection period (PEP) and preejection period/left ventricular ejection time (PEP/LVET) ratio between subjects treated with ACTH 1-17 and subjects receiving placebo. As expected, a significant increase of cortisol and aldosterone plasma levels was observed in subjects treated with ACTH 1-17. The difference of adrenaline and noradrenaline plasma levels was statistically highly significant between subjects treated with ACTH 1-17 and those receiving placebo. The lack of increase in PEP and PEP/LVET ratio recorded in subjects treated with ACTH 1-17 is consistent with an increased left ventricular contractile performance. An increased plasma catecholamine release is postulated as the mechanism of this improvement.